The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
" Visibility of orders for the Company's COVID-19 product portfolio suggests H2 2020 performance on track to exceed that of H1 2020" ................... sounds good to me
Shanjo ,why spending so much time here with negative posts
France up nice 5%
@ShanJO - did you miss the boat here pal? Still time to jump on board
IN TODAYS RNS
Financial highlights
• Group consolidated unaudited revenue increased over 900% to €72.4m (H1 2019: €7.2m)
• Primerdesign revenue increased over 2,000% to €70.6m (H1 2019: €3.3m) due to the success of the COVID-19 product portfolio
• Group gross margin strengthened to 83%, delivering a gross profit of €60.3m, an increase of 20% from H1 2019 (63%)
• Primerdesign maintained its strong gross margin, delivering 85% in H1 2020 (H1 2019: 86%), demonstrating strong control of margins as the business is scaled
• Group EBITDA of €49.4m (H1 2019: €0.2m)
• Operating profit of €48.3m compared to a loss of €0.7m in H1 2019, driven by the growth in sales in molecular products business
• Profit after tax of €40.2m compared to a loss of €1.2m in H1 2019
• Cash at 30 June 2020 of €19.7m after paying down all long-term debt and significant working capital investment made into stock to ensure the continuity of supply to meet the demand for COVID-19 tests
The message is clear, an acquisition is on the way - and you clearly aren’t going to emphasise how much cash you have on hand during negotiations! Results are brilliant, the margin is sensational, very impressive to scale & maintain that level of control.
There you Shan its 8pm.. QUICK sell sell sell!!
Exmex- Antibody partner AZ IMO.
@Shanjo
Roll on 8am when you can sell up and move on out , waste of space...
Shanjo we have got the message sell and go!
Also that is just making the assumption we duplicate sales as per H1. This is going to be an interesting year!
Based on that alone - this will be up 15 percent today - in my opinion!
Antibody test to be launched by the end of the month .Who has managed to work out the partner for this?
This is the key bit. “Full year revenues are expected to exceed €150 million and EBITDA profitability to exceed €100 million. The Company expects this rate of financial performance to extend into the first half of 2021.” So we are trading on 2 times revenue and 3 profit. Looks cheap to me considering this is expected to last until end of June 2021 at least
Transformational - the key word.
Of all the Covid diagnostic related stocks, Novacyt is most adaptable to change.
Success doesn't come to you - you go to it.
Good results, better than any UK covid company.
And with wave 2 already started the forecast will be higher profits by year end.
Shanjo, you should save your energy and posts for AVCT and ODX when they post their EBITDA numbers.
We're making a great profit every month and with a real potential of landing major contracts in UK, France and America.
Nice solid base created now that the slow part of the year is out of the way, onward and upward into the 2nd very progressive and exciting part. Starters out of the way, bring on the main course. GLA.
ShanJo - One thing that will drop is UJO upon placing .. You won’t get that problem here.
Perhaps you should have bought a few here instead of getting spiked over there.
There’s still time for you to make your money back by getting a few over here..
A mere history lesson!
Nothing in these figures that wasn't already known or assumed.
Negative comments are either from those who have not been doing any research, or from those wishing to see the SP drop.
This RNS will just add remind the educated investors that NCYT are one of few Covid players who have actually delivered substantial profit from an early stage - and post June 2020 it looks even rosier!
Upward trend to continue.
"What you mean only 19M cash do you run your own company that has more than that? No? Sit back down with your negativity"
Who are you responding to pacaso?
If the company were to be rated at 20X this years earnings the sp would multiply by at least 4. I don;t think that is justified because this year is a special year , nevertheless an upward re rate looks justifiable imv.
We get it you're a deramper, now give it a rest. No one cares if you take profit, there's no need to announce it
"I'm taking profits . This could drop."
Based on results that were already known or better than expected? Why would you think that
And why would you hold if you get results in line with what we have already been told?
What you mean only 19M cash do you run your own company that has more than that? No? Sit back down with your negativity
We had these figures in the July 13th update. The comments this morning are obviously people unhappy the price has risen from the 300p base in the last week and now want to scare people into selling to get a better entry. We all know where this company is headed and that's mid-cap status. They will have another 40-50million profit by the end of 2020 to add to the cash balance at the end of June which is an amazing position to be in. Strap in for the ride I say!